GlobeNewswire: Paratek Pharmaceuticals Contains the last 10 of 296 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:13:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/10/05/2755325/0/en/Paratek-Pharmaceuticals-to-Present-NUZYRA-Data-at-IDWeek-2023.html?f=22&fvtc=4&fvtv=23957Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 20232023-10-05T12:00:00Z<![CDATA[BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.]]>https://www.globenewswire.com/news-release/2023/09/21/2747312/0/en/Gurnet-Point-Capital-and-Novo-Holdings-A-S-Complete-Acquisition-of-Paratek-Pharmaceuticals-Inc.html?f=22&fvtc=4&fvtv=23957Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.2023-09-21T12:58:57Z<![CDATA[CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).]]>https://www.globenewswire.com/news-release/2023/09/18/2744909/0/en/Paratek-Pharmaceuticals-Announces-Stockholder-Approval-of-Acquisition-by-Gurnet-Point-Capital-and-Novo-Holdings-A-S.html?f=22&fvtc=4&fvtv=23957Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S2023-09-18T13:37:40Z<![CDATA[BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek’s special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings").]]>https://www.globenewswire.com/news-release/2023/09/12/2741540/0/en/Second-Leading-Independent-Proxy-Advisory-Firm-Glass-Lewis-Recommends-Paratek-Pharmaceuticals-Stockholders-Vote-FOR-the-Acquisition-by-Gurnet-Point-Capital-and-Novo-Holdings-A-S.html?f=22&fvtc=4&fvtv=23957Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S2023-09-12T11:30:00Z<![CDATA[Follows the recommendation from ISS to vote FOR the transaction Follows the recommendation from ISS to vote FOR the transaction]]>https://www.globenewswire.com/news-release/2023/08/03/2717981/0/en/Paratek-Pharmaceuticals-Announces-Second-Quarter-2023-Revenue-of-40-0-Million.html?f=22&fvtc=4&fvtv=23957Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million2023-08-03T12:00:00Z<![CDATA[-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022]]>https://www.globenewswire.com/news-release/2023/08/02/2717520/0/en/Paratek-Pharmaceuticals-Files-Definitive-Proxy-Statement-and-Letter-to-Stockholders-in-Connection-with-Acquisition-by-Gurnet-Point-Capital-and-Novo-Holdings.html?f=22&fvtc=4&fvtv=23957Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings2023-08-02T21:36:04Z<![CDATA[Transaction Provides Paratek Stockholders with Immediate Value and Liquidity]]>https://www.globenewswire.com/news-release/2023/07/10/2701714/0/en/Paratek-Pharmaceuticals-Announces-Modification-of-BARDA-Contract-to-Advance-the-Development-of-NUZYRA-omadacycline-for-Post-Exposure-Prophylaxis-PEP-and-Treatment-of-Pulmonary-Anth.html?f=22&fvtc=4&fvtv=23957Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax2023-07-10T12:00:00Z<![CDATA[-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024]]>https://www.globenewswire.com/news-release/2023/06/27/2695623/0/en/Paratek-Pharmaceuticals-Acknowledges-Receipt-of-NexPoint-Letter.html?f=22&fvtc=4&fvtv=23957Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter2023-06-27T16:01:04Z<![CDATA[BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today acknowledged receipt of a letter from NexPoint Asset Management, L.P., together with its affiliates (collectively, "NexPoint").]]>https://www.globenewswire.com/news-release/2023/06/27/2695236/0/en/European-Medicines-Agency-COMP-Recommends-Positive-Opinion-on-Orphan-Medicinal-Product-Designation-for-NUZYRA-omadacycline-for-Treatment-of-Nontuberculous-Mycobacterial-NTM-Lung-Di.html?f=22&fvtc=4&fvtv=23957European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease2023-06-27T12:00:00Z<![CDATA[BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended a positive opinion for orphan medicinal product designation for NUZYRA® (omadacycline) for the treatment of nontuberculous mycobacterial (NTM) lung disease. The COMP opinion applies to all species of NTM, including Mycobacterium abscessus (MAB) and Mycobacterium avium complex (MAC).]]>https://www.globenewswire.com/news-release/2023/06/12/2686254/0/en/Paratek-Pharmaceuticals-Presenting-New-Data-from-NUZYRA-omadacycline-and-Investigator-Initiated-Research-Programs-at-ASM-Microbe-2023.html?f=22&fvtc=4&fvtv=23957Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 20232023-06-12T12:00:00Z<![CDATA[BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) will be presented at ASM Microbe 2023 conference.]]>